Chebulinic acid

Other Names

1,3,6-tri-O-galloyl-2,4-chebuloyl-beta-D-glucose2-[(4R,5S,7R,8R,11S,12S,13S,21S)-13,17,18-trihydroxy-2,10,14-trioxo-5,21-bis[(3,4,5-trihydroxybenzoyl)oxy]-7-[(3,4,5-trihydroxybenzoyl)oxymethyl]-3,6,9,15-tetraoxatetracyclo[10.7.1.14,8.016,20]henicosCHEBI:3584EutanninNSC 69862NSC69862β-D-Glucopyranose, 1,3,6-tris(3,4,5-trihydroxybenzoate), cyclic 2→2:4→1-ester with (2S)-[(3R,4S)-5-carboxy-3,4-dihydro-3,7,8-trihydroxy-2-oxo-2H-1-benzopyran-4-yl]butanedioic acidβ-D-Glucopyranose, cyclic 2,4-ester with 3-(6-carboxy-2,3,4-trihydroxyphenyl)-4-hydroxy-1,2,4-butanetricarboxylic acid, 1,3,6-tris(3,4,5-trihydroxybenzoate)

Synopsis

Chebulinic Acid: A Comprehensive Reference

1. Identity: Chemical and Botanical Profile

1.1 Chemical Classification and Structure

Chebulinic acid is a natural product in the family of ellagitannins, or hydrolyzable tannins, which consist of polyphenols surrounding a glucose center. As an ellagitannin, it belongs to the broader class of polyphenolic compounds whose core structure involves ester bonds between gallic and hexahydroxydiphenic (HHDP) acid units linked to a glucose moiety. These ester bonds are susceptible to hydrolysis, which distinguishes hydrolyzable tannins from condensed tannins. Its molecular formula is C₄₁H₃₂O₂₇, listed under PubChem CID 72284. Its molecular mass is approximately 956 daltons, as recorded in chemical databases. Chebulinic acid is distinct from — though chemically related to — chebulagic acid, another major ellagitannin found in the same plant sources.

1.2 Discovery and Nomenclature

Chebulinic acid has been known since 1911, when German scientist W. Richter described it under the name "eutannin." In 2006, Hongxi Xu and co-workers at the Hong Kong Jockey Club Institute of Chinese Medicine reported the preparative isolation of it and the similar molecule chebulagic acid. The compound is also sometimes referred to as chebulinic acid (CA) or CI in pharmacological literature, and should not be confused with the structurally simpler "chebulic acid," which is a distinct compound with a different molecular formula.

1.3 Botanical Sources

The compound is found in plants such as Euphoria longana and Terminalia chebula (both tropical Asian fruit trees) and T. macroptera (a central African flowering tree). Of these sources, Terminalia chebula is by far the most studied and commercially significant. T. chebula, commonly known as Myrobalan (Haritaki), belongs to the Combretaceae family. It is a well-known traditional medicine extensively used in Ayurvedic, Homeopathic, Unani, and Tibetan systems, and is called the "King of medicine" in Tibetan medicine. It is mainly found in India and South-East Asia.

Chebulinic acid (CA) is a major chemical constituent of T. chebula fruit. The fruit has been examined in both ripe and unripe forms. T. chebula contains diverse bioactive compounds such as chebulic acid, chebulinic acid, gallic acid, corilagin, punicalalagin, and casuarinin. Other co-occurring tannins and phenolic constituents include chebulagic acid, ellagic acid, terchebulin, corilagin, punicalagin, terflavin A and B, neochebulinic acid, and 1,2,3,4,6-penta-O-galloyl-β-D-glucose.

1.4 Common Forms and Preparations

Chebulinic acid occurs naturally as part of the whole-fruit preparation of T. chebula, known as Chebulae Fructus or Haritaki in Ayurveda, and as an ingredient of the classical poly-herbal formulation Triphala. Triphala is a critical herbal blend in Ayurveda consisting of three medicinal fruits: Terminalia chebula Retz., Phyllanthus emblica Linn., and Terminalia belerica Retz. In research and pharmaceutical contexts, chebulinic acid is isolated as a pure compound using techniques such as high-speed counter-current chromatography and semi-preparative liquid chromatography. In modern isolations, it is identified through Ultra-high performance liquid chromatography-MS/MS (UPLC–MS/MS) and Nuclear Magnetic Resonance (NMR). Research-grade or supplement-grade preparations include standardized fruit extracts, Triphala formulations, and more recently, novel delivery systems such as solid dispersions designed to improve bioavailability.

2. Traditional and Historical Use

2.1 Ayurveda

The myrobalan (Terminalia chebula) was renowned as the king of medicinal plants in Ayurveda due to its wide range of utilization in herbal decoctions to treat various health disparities. The whole fruit or its preparations constitute a major Ayurvedic Rasayana — a tonic regarded as promoting vitality and longevity. In Ayurveda, ripe dried fruits (Haritaki phala) are predominantly used, though leaves and bark sometimes enter formulations. The Charaka Samhita and the Sushruta Samhita, foundational Ayurvedic texts, both describe the fruit's use; the classical Sushruta Samhita text highlights its use in over 20 ancient preparations focusing on bowel health, wound healing, and respiratory support. Triphala, the tripartite formulation containing T. chebula, has been used for centuries as a digestive tonic, laxative, and liver support preparation.

2.2 Tibetan Medicine

Terminalia chebula Retz, known as the "King of Tibet," is considered a functional food in China, celebrated for its antioxidant, immune-modulating, antibacterial, and anti-inflammatory properties. In Tibetan medical iconography, the plant occupies a sacred role: the Buddha is often depicted holding a Haritaki fruit as a symbol of medicine and healing. The fruit appears extensively in Tibetan pharmacopeias and was prepared as decoctions, powders, and fermented beverages.

2.3 Traditional Chinese Medicine

Hydrolyzable tannins from the fruits and leaves of plants that contain chebulinic acid are used in traditional Chinese medicine. Terminalia chebula Retz., known for its dried fruit, namely Chebulae Fructus, is a medicinal plant with a long-standing global reputation, which was initially recognized for its therapeutic properties during the Jin Dynasty. In Chinese tradition, the fruits were used for conditions including chronic diarrhea, dysentery, sore throat, and hoarseness, and were prepared as water-based decoctions or powdered forms.

2.4 Unani Medicine

Terminalia chebula has been traditionally used in Ayurveda, Unani, and Chinese medicine for centuries. In the Unani system, the fruit (known as Halilaj or Harad) was employed for digestive disorders, respiratory conditions, and as an astringent for wounds, consistent with the tannin content of the fruit including chebulinic acid.

2.5 Fermented Preparations

Chemical changes occurring during the fermentation process of Abhayarishta (an Ayurvedic formulation) — traditionally prepared from the fermentation of Embelia ribes (fruits), Terminalia chebula (pericarp), Vitis vinifera (fruits), and Madhuca indica (flowers) decoction — have been characterized by HPLC-DAD method. Chebulinic acid is among the constituents monitored in such preparations, though fermentation may alter its concentration and bioavailability.

3. Key Constituents, Co-occurring Compounds, and Phytochemical Context

While chebulinic acid is the focus of this article, its pharmacological profile in whole-plant preparations is inseparable from the broader phytochemical context of T. chebula. The current phytochemical profile of the plant includes phenolic acids, casuarinin, chebulagic acid, chebulinic acid, rutin, and corilagin. These compounds often act synergistically.

Chebulinic acid's closely related structural analog, chebulagic acid, shares many biological activities. Both are ellagitannins produced from the same plant; their co-isolation from T. chebula fruit was first described using preparative chromatographic methods in 2006. Anti-inflammatory and anti-oxidant properties of Triphala and its active constituents such as chebulagic acid, chebulinic acid, and gallic acid have been previously studied, and studies have shown that the active constituents of Triphala inhibit TNF-alpha induced angiogenesis and inflammation in retinal microvascular endothelial cells.

Other tannins co-occurring with chebulinic acid in T. chebula include corilagin, terchebulin, punicalagin, terflavin B, and neochebulinic acid. Modern pharmacological studies show extensively that tannins such as chebulinic acid, chebulagic acid, ellagic acid, and corilagin, alongside phenolic acids such as gallic acid, protocatechuic acid, and ethyl gallate, are the main bioactive components underpinning the pharmacological effects of T. chebula.

4. Mechanisms of Action

4.1 Antioxidant Activity

Chebulinic acid efficiently scavenges free radicals, safeguarding cells against oxidative harm. At the molecular level, a key pathway through which it exerts antioxidant cytoprotection is the Nrf2/HO-1 axis. This protective effect is primarily achieved by inhibiting the production of reactive oxygen species (ROS), reducing lactate dehydrogenase (LDH) levels, and boosting the expression of HO-1 and NADPH quinone dehydrogenase 1 (NQO1) through the MAPK/Nrf2 signaling pathway. In related animal studies, chebulinic acid significantly shielded mice from liver damage induced by carbon tetrachloride (CCl₄). This was evidenced by decreased levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and malondialdehyde (MDA), along with increased superoxide dismutase (SOD) activity, improved liver histopathology, and activation of the Nrf2/HO-1 signaling pathway.

4.2 Anti-inflammatory Activity

Compounds such as corilagin, chebulanin, chebulagic acid, and chebulinic acid are cited for their efficacious impact in mitigating arthritis symptoms. Their anti-inflammatory activity is mainly achieved through the NF-κB and MAPK signaling pathways. At the cellular level, chebulinic acid notably reduces the production of pro-inflammatory cytokines and effectively downregulates the phosphorylation of NF-κB and IκBα. Chebulinic acid has been found to possess anti-inflammatory properties in LPS-stimulated macrophages by inhibiting iNOS and COX-2 enzymes.

4.3 Antiangiogenic Activity (VEGF Inhibition)

Chebulinic acid (CI), a water-soluble small-molecule tannin, can inhibit the actions of VEGF, and a report suggested that CI might not increase blood pressure due to its compensatory effects on the cardiovascular system. At the receptor level, chebulinic acid inhibits VEGF-mediated angiogenesis through inhibition of vascular endothelial growth factor receptor-2 (VEGFR-2) phosphorylation, and downregulates expression of the VEGF-dependent vascular genes ESM 1 and Apelin. Further studies showed that chebulinic acid greatly inhibited the activation of Erk1/2, p38 MAPK, and AKT phosphorylation in human synovial microvascular endothelial cells (HSMECs).

4.4 Anticancer Pathways

Chebulinic acid exerts potent anti-proliferative, pro-apoptotic, and anti-migratory effects, and is a key molecule for maintaining the antitumour efficacy of Triphala. The antitumour mechanism of chebulinic acid is probably related to the PI3K/AKT and MAPK/ERK pathways.

4.5 Antidiabetic Pathways

The antidiabetic potential of chebulinic acid is caused by dual inhibition of PTPN9 and PTPN11, which results in increased glucose uptake through activation of the AMPK (AMP-activated protein kinase) signaling pathway. This study suggests chebulinic acid (CA) could be used as a potential therapeutic agent for the management of type 2 diabetes.

4.6 Gastroprotective Pathways

Chebulinic acid has shown significant efficacy in treating gastric ulcers due to its anti-secretory, anti-oxidative, and cytoprotective properties, as well as its ability to inhibit H⁺K⁺-ATPase activity. Chebulinic acid protects the stomach by inhibiting the activity of the H⁺K⁺-ATPase (proton pump) enzyme, indicating that it might represent an effective treatment to reduce the incidence of gastric ulcers (chebulinic acid at a dose of 40 mg/kg has demonstrated anti-gastric ulcer effect in preclinical models).

4.7 Anti-Adhesion and Antimicrobial Mechanisms

Chebulinic acid has a distinctive chemical structure and biological activity that enables it to specifically bind to particular receptors on the surface of host cells, endowing it with the ability to modulate bacterial adhesion across multiple levels. Previous research demonstrated that chebulinic acid inhibits the binding of HIV-1 gp120 to CD4, thereby exhibiting anti-HIV activity. More recently, chebulinic acid has been identified as a novel potential antifungal agent against Candida glabrata, acting by binding to the CgMed15a KIX domain.

5. Scientific Evidence by Area of Use

5.1 Hepatoprotection (Liver Health)

The fruit of Terminalia chebula Retz. is one of the most widely used herbal drugs in traditional medicine prescriptions, including those for liver diseases. Scientific investigation has provided cell-line and animal-model evidence for chebulinic acid's hepatoprotective potential. The hepatoprotective effect of chebulinic acid (CA) was examined on hepatotoxic models of cells, zebrafish larvae, and mice caused by tert-butyl hydrogen peroxide (t-BHP), acetaminophen (APAP), and CCl₄, respectively. Pretreatment with CA could prevent t-BHP-induced damage in L-02 hepatocytes by blocking the production of ROS, reducing LDH levels, and enhancing HO-1 and NQO1 expression via the MAPK/Nrf2 signaling pathway.

Studies conducted on cells and in animal models have consistently demonstrated and elaborated the hepatoprotective effects of chebulinic acid. Chebula Fructus water extract effectively shields the liver from acute and severe damage, with potential mechanisms including boosting antioxidant capabilities and regulation of inflammatory responses.

Evidence strength: All available evidence is preclinical (cell lines, zebrafish, and rodent models). No human clinical trials have been conducted specifically investigating chebulinic acid's hepatoprotective effects as an isolated compound.

5.2 Anti-inflammatory and Arthritis

The anti-arthritic evidence for chebulinic acid in preclinical models is among the most detailed in its research literature. A 2020 study published in Arthritis Research & Therapy investigated chebulinic acid specifically in a murine collagen-induced arthritis (CIA) model. This study indicated for the first time that CI, a water-soluble, orally bioavailable small molecule, could significantly improve disease activity in mice with CIA by inhibiting VEGF-induced angiogenesis through molecular mechanisms not reported before.

Chebulinic acid has been described to reduce inflammatory manifestations in CIA mice by inhibiting CD31 expression and VEGF. Degenerative changes and inflammatory damage in osteoarthritis were also notably attenuated by chebulinic acid administration.

Regarding inflammatory bone loss, the findings concerning the protective effects of chebulinic acid on LPS-induced bone loss suggest its promise as a potential novel therapeutic strategy for bone-related inflammatory diseases. Micro-CT analysis and histomorphometric evaluations found that chebulinic acid significantly improved bone micro-architectures by enhancing trabecular connectivity and strength of the bone.

Since hypertension and associated cardiovascular complications are common in RA patients, and because results demonstrated that CI does not increase blood pressure, clinical trials may be undertaken in the future to evaluate the efficacy of CI in RA patients, either alone or in combination with other agents currently used for the treatment of RA.

Evidence strength: Preclinical (rodent CIA and LPS-induced bone-loss models). No published human clinical trials for chebulinic acid as an isolated compound in arthritis or inflammatory joint disease. Mechanistic data are robust at the in vitro and animal level.

5.3 Gastrointestinal Health and Gastric Ulcers

The antiulcer properties of chebulinic acid have been investigated in rat ulcer models. In continuation of a drug discovery program on Indian medicinal plants, the gastroprotective mechanism of chebulinic acid isolated from Terminalia chebula fruit was investigated. Chebulinic acid was evaluated against cold restraint (CRU), aspirin (AS), alcohol (AL), and pyloric ligation (PL)-induced gastric ulcer models in rats. Potential anti-ulcer activity of chebulinic acid was observed against CRU (62.9%), AS (55.3%), AL (80.67%), and PL (66.63%) induced ulcer models. For reference, the reference drug omeprazole (10 mg/kg, p.o.) showed 77.73% protection against CRU, 58.30% against AS, and 70.80% against PL model.

A 2024 study published in Frontiers in Microbiology specifically investigated chebulinic acid's activity against Helicobacter pylori, a major causative factor in peptic ulcers and gastric cancer. Results showed that chebulinic acid effectively inhibited the growth of the HP strain ATCC 700392, damaged the HP structure, and exhibited selective antimicrobial activity without affecting normal epithelial cells GES-1. Experimental findings have demonstrated that chebulinic acid suppresses the expression of CagA. Molecular docking analysis was employed to explore the interaction between chebulinic acid and CagA, revealing a predicted binding affinity of −9.7 kcal/mol. Overall, these findings suggest that chebulinic acid acts as an anti-adhesive agent, disrupting the adhesion of HP to host cells, which is a critical step in HP infection. It also suppresses the CagA protein.

Evidence strength: Preclinical (rat ulcer models) and in vitro cell/molecular docking data for H. pylori. No human clinical trials specifically for chebulinic acid as an isolated compound in gastrointestinal indications.

5.4 Antidiabetic Effects

The aqueous extract of Terminalia chebula fruits has been reported to possess anti-diabetic and anti-hyperglycemia potential. At the molecular pharmacology level, the antidiabetic potential of chebulinic acid is caused by dual inhibition of PTPN9 and PTPN11, which results in increased glucose uptake through activation of the AMPK (AMP-activated protein kinase) signaling pathway. This study suggests chebulinic acid (CA) could be used as a potential therapeutic agent for managing type 2 diabetes. In another study, Terminalia chebula fruit extracts (hexane, ethyl acetate, methanol, and methanol-water) were evaluated for their α-glucosidase inhibitory activity, which resulted in significant antidiabetic property.

Evidence strength: In vitro enzyme inhibition and molecular docking studies, with some in vivo rodent evidence for the whole-fruit extract. No published human clinical trials isolating chebulinic acid's antidiabetic effects in human subjects.

5.5 Anticancer Properties

Research indicates potential anticancer properties of chebulinic acid through apoptosis induction and inhibition of cancer cell proliferation, positioning it as a promising candidate for cancer prevention and treatment. In colorectal carcinoma cell-line studies, the anti-proliferative activities of chebulinic acid were evaluated in colorectal carcinoma cell lines with three phenotypes. The pro-apoptotic and anti-migratory activities and the probable antitumour mechanisms were also investigated. The results demonstrated that chebulinic acid, which exerts potent anti-proliferative, pro-apoptotic, and anti-migratory effects, is a key molecule for maintaining the antitumour efficacy of Triphala.

Both T. chebula and chebulinic acid are currently being explored for their anticancer potential in vitro and in vivo. In addition, chebulinic acid has also been explored for its anti-tumour and anti-oxidant property in colorectal carcinoma cell lines.

Evidence strength: Preliminary — in vitro (cell-line) and animal models only. No human clinical trials have evaluated chebulinic acid's anticancer potential as an isolated compound. The anticancer evidence base is entirely preclinical at this stage.

5.6 Antiviral Effects

Chebulinic acid has been investigated against a range of viral pathogens. Two related compounds, chebulagic acid (CHLA) and chebulinic acid (CHLI), were identified as novel inhibitors against IAV (influenza A virus) replication. The mechanism involves inhibition of neuraminidase, the enzyme critical for viral release from host cells. A reporter virus-based infection assay demonstrated that CHLA and CHLI exhibit no inhibitory effect on IAV entry or RNA replication during the virus replication cycle, indicating that their inhibitory activity is specifically directed at the neuraminidase-mediated release stage rather than earlier stages of viral replication.

Also in 2022, researchers at the Central University of Rajasthan and the National Institute of Virology (Pune, India) reported other benefits of chebulinic acid. Noting that the acid had showed the ability to inhibit herpes simplex virus-2 infections, they used in vitro and in silico methods to determine whether it is active against the dengue and chikungunya viruses.

Chebulinic acid demonstrates broad-spectrum antimicrobial activity against bacteria, fungi, and viruses, aligning with its traditional use in treating infections and promoting overall health.

Evidence strength: In vitro and in silico studies. No clinical trials in humans for any antiviral indication specifically using chebulinic acid as an isolated compound.

5.7 Antimicrobial (Bacterial) Effects

Literature surveys reveal that Terminalia chebula plant extracts possess good antibacterial activity against multidrug-resistant clinical strains of Acinetobacter baumannii. Four compounds — chebulinic acid, chebulagic acid, terchebulin, and corilagin — were identified on the basis of bioactive-guided fractions of the plant extract using HPLC to possess antimicrobial activity against A. baumannii.

Evidence strength: In vitro minimum inhibitory concentration (MIC) studies. No human clinical data.

5.8 Cardiovascular and Antihypertensive Effects

Research has concluded that chebulinic acid exerts a reversible non-specific inhibitory effect on cardiac contraction on vascular preparations. Additionally, chebulinic acid has been studied in the context of antiatherogenesis. Its known ability to suppress ROS, NF-κB, and inflammatory cytokines is mechanistically relevant to atherogenesis. The compound also appears under "antihypertensive activity" in studies of tannins from related plant species (e.g., Lumnitzera racemosa).

Evidence strength: Predominantly in vitro and ex vivo vascular preparations; animal models. No human clinical trials for isolated chebulinic acid in cardiovascular disease.

5.9 Neuroprotective Effects

Preclinical evidence suggests neuroprotective potential. In a study of ischemic stroke models, a related compound chebulic acid was investigated, but the mechanistic insight is relevant to the broader ellagitannin class: the compound acted as an antioxidant indirectly by upregulating antioxidant-responsive-element (ARE) and Nrf2 nuclear translocation to relieve oxygen-glucose deprivation/reoxygenation (OGD/R)-induced oxidative damage. Furthermore, treatment resulted in a significant decrease in ischemic infarct volume and improved performance in the motor ability of mice 24 hours after stroke.

Chebulinic acid has been described as an active constituent of Terminalia chebula fruits with therapeutic potential against multiple metabolic diseases, including dementia, benign prostate hyperplasia, and osteoporosis.

Evidence strength: Preclinical rodent models and in vitro cell studies. No human evidence for chebulinic acid specifically in neurological indications.

6. Body Systems and Health Areas Associated with Chebulinic Acid

Gastrointestinal system: Gastroprotection, gastric ulcer inhibition (H⁺K⁺-ATPase inhibition), anti-H. pylori, and bowel regulatory tonic (in whole-fruit preparations)
Musculoskeletal/Immune system: Anti-arthritic (VEGF and angiogenesis inhibition in RA models); anti-inflammatory bone protection (LPS-induced bone loss)
Hepatic system: Hepatoprotection against chemical-induced (CCl₄, APAP, t-BHP) liver injury via Nrf2/MAPK pathways
Oncology: In vitro anti-proliferative, pro-apoptotic, and anti-migratory activity in colorectal carcinoma cell lines; mechanistic activity via PI3K/AKT and MAPK/ERK pathways
Endocrine/metabolic: Antidiabetic activity through AMPK activation and dual inhibition of PTPN9/PTPN11; α-glucosidase inhibition
Cardiovascular system: Antiatherogenic (ROS/NF-κB suppression); reversible cardiac effects on vascular preparations
Microbiology/Infectious diseases: Antiviral (influenza A neuraminidase inhibition; HSV-2; dengue; chikungunya); antibacterial (A. baumannii, H. pylori); antifungal (C. glabrata)
Nervous system: Preclinical neuroprotective effects in stroke/ischemia models via Nrf2/ARE pathway

7. Dosage Forms and Reported Dosages

No standardized human clinical dosage for chebulinic acid as an isolated compound has been established. The dosages reported below are exclusively from preclinical (animal or in vitro) research as stated in the cited sources.

Chebulinic acid at a dose of 40 mg/kg demonstrated anti-gastric ulcer effect in preclinical models.
In a pharmacokinetic study in male SD rats, chebulinic acid demonstrated moderate oral bioavailability at 37.56 ± 7.3% when administered at a dosage of 100 mg/kg.
In the murine CIA (collagen-induced arthritis) study at Arthritis Research & Therapy (2020), CI was administered orally in mice, and demonstrated significant improvement in disease activity. The study characterized it as a water-soluble small-molecule tannin.
Acute toxicity studies in female Sprague-Dawley rats showed no morbidity and mortality after oral ingestion of chebulinic acid at 300 and 2000 mg/kg.

In formulation research, a solid dispersion-loaded gastroretentive raft system has been investigated as a delivery vehicle for chebulinic acid to improve its residence time and bioavailability at the gastric mucosa; however, this remains at the preclinical stage. Efforts are being made to improve the bioavailability by developing novel herbal drug delivery systems of the plant extract or chebulinic acid itself.

8. Pharmacokinetics

The elimination half-lives (T₁/₂) for chebulinic acid, corilagin, and chebulagic acid were found to be 43.30, 26.39, and 19.98 h, respectively, indicating that these compounds are retained and slowly metabolized in the body for extended periods of time. The plasma protein binding of chebulinic acid was found to be 84.81 ± 7.70% and 96.34 ± 3.12%, with a blood-to-plasma ratio of 0.62 ± 0.16 and 0.80 ± 0.23 at 1 μM and 10 μM concentrations, respectively.

Pharmacokinetic parameters reveal chebulinic acid to have an affinity to distribute across different extravascular tissues and to induce rat liver CYP enzymes. It is important to note that natural products often exhibit low water solubility and bioavailability, a limitation that applies to chebulinic acid and has motivated the development of enhanced formulation strategies.

9. Safety Considerations and Drug Interactions

9.1 Acute Toxicity

Results in female Sprague-Dawley rats highlighted no morbidity and mortality after oral ingestion of chebulinic acid at 300 and 2000 mg/kg. Food and water consumption, body weight, relative organ weight, hematological and biochemical parameters were normal without any gross pathological lesions in harvested tissues. Similarly, acute toxicity studies of T. chebula preparations did not show any morbidity and mortality at various doses.

9.2 Cytochrome P450 Enzyme Induction

A pharmacokinetic study published on PubMed (2023) identified a potentially important drug interaction concern: the absolute oral bioavailability of chebulinic acid at 100 mg/kg was found to be 37.56 ± 7.3%. The in vivo pharmacokinetic profile of probe drugs revealed chebulinic acid to have significant inducing effects on CYP1A2, 2C11, 2D2, and 2E1 after 14 days, which correlates to both in vitro rat microsomal data and gene expression results. Such induction of cytochrome P450 enzymes could influence the metabolism of other drugs and potentially modify therapeutic outcomes. Overall, these findings suggest that chebulinic acid not only possesses beneficial pharmacological properties but also exhibits a complex interaction with liver enzymes that could impact its therapeutic efficacy and drug interactions.

CYP1A2, CYP2D, and CYP2E1 are enzymes involved in the metabolism of a wide range of pharmaceutical drugs. Induction of these enzymes — as observed in the preclinical data — could theoretically reduce plasma levels of co-administered drugs that are metabolized by these pathways. This is an area requiring further investigation in humans before clinical use can be characterized.

9.3 Absence of Human Safety Data

Despite long-term use of natural products containing chebulinic acid, there is a lack of records on the safety profile. Such a dearth of documentation has motivated researchers to find in-depth characterization of phytocompounds, including evaluation of their toxicities, and greater attention should be given to ensuring the safety and efficacy of dietary supplements and traditional medicinal agents. No formal human clinical safety trials specifically for isolated chebulinic acid have been published in the peer-reviewed literature as of the time of this writing.

9.4 Tannin-Specific Considerations

As a high-molecular-weight, polyphenolic hydrolyzable tannin, chebulinic acid shares certain class-wide characteristics relevant to its use. High-tannin preparations can chelate dietary minerals (iron, zinc) and may interfere with protein digestion when taken in large quantities. These are properties common to polyphenolic tannins as a class and have not been specifically quantified for isolated chebulinic acid in human studies.

10. Current Research Landscape and Evidence Limitations

Chebulinic acid has been widely studied for its pharmacological properties. Reviews have examined biological properties, including antitumor activity and antiatherogenic, antifibrotic, anti-inflammatory, antiulcer, antioxidant, hepatoprotective, antidiabetic, and antiviral effects attributable to ellagitannins, and recommended further studies in these pathology areas.

As of the time of this writing, the entire evidence base for chebulinic acid as an isolated compound consists of in vitro cell-line studies, in silico molecular docking analyses, and in vivo rodent models. No randomized controlled trials (RCTs) or other formal human clinical trials have been published for chebulinic acid as a purified compound. Clinical evidence for the whole-plant preparation (T. chebula or Triphala) does exist, but cannot be directly attributed to chebulinic acid alone, as these preparations contain numerous bioactive polyphenols acting in concert.

The research community has identified chebulinic acid as an important bioactive lead and a "key molecule" within Triphala's anti-tumour activity, but translating these findings to clinical practice requires studies in humans that have yet to be conducted. Efforts are being made to improve bioavailability by developing novel herbal drug delivery systems that could make such clinical studies feasible. The CYP enzyme induction data represent an important safety signal that warrants prospective investigation in any future clinical program.

References

Health Conditions

Health conditions that Chebulinic acid may help support.

No conditions available.

Body Systems

Body systems that Chebulinic acid may help support.

No body systems available.